Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...
Sanofi, rival drugmakers Lilly, Boehringer settle suit allowing rival to Lantus insulin in US This product image provided by Sanofi shows Lantus SoloStar, the French drugmaker's once-daily insulin in ...
TRENTON, N.J. — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over ...
Sanofi SNY came up with two important announcements related to its diabetes drugs, Lantus and lixisenatide (EU trade name: Lyxumia). Lantus Biosimilar Could Hit U.S. Markets by 2016 End Sanofi ...
The US FDA has approved Eli Lilly’s Basaglar, a ‘follow-on’ of Sanofi’s $8bn-a-year basal insulin product Lantus. Basaglar (insulin glargine) is the first insulin product to be approved via the ...
Credit: Getty Images. Rezvoglar may now be substituted for Lantus at the pharmacy counter without the need for an intervention from the prescriber. The Food and Drug Administration (FDA) has approved ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results